- Home
- DTIL vs IRD Comparison
DTIL vs IRD Comparison
Compare DTIL & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- IRD
- Stock Information
- Founded
- DTIL 2006
- IRD 2018
- Country
- DTIL United States
- IRD United States
- Employees
- DTIL N/A
- IRD N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- IRD
- Sector
- DTIL Health Care
- IRD
- Exchange
- DTIL Nasdaq
- IRD NYSE
- Market Cap
- DTIL 43.3M
- IRD 35.7M
- IPO Year
- DTIL 2019
- IRD N/A
- Fundamental
- Price
- DTIL $5.93
- IRD $1.10
- Analyst Decision
- DTIL Strong Buy
- IRD Strong Buy
- Analyst Count
- DTIL 3
- IRD 1
- Target Price
- DTIL $37.67
- IRD $8.00
- AVG Volume (30 Days)
- DTIL 123.5K
- IRD 167.3K
- Earning Date
- DTIL 03-26-2025
- IRD 03-04-2025
- Dividend Yield
- DTIL N/A
- IRD N/A
- EPS Growth
- DTIL N/A
- IRD N/A
- EPS
- DTIL 1.45
- IRD N/A
- Revenue
- DTIL $75,096,000.00
- IRD $8,381,000.00
- Revenue This Year
- DTIL $51.35
- IRD N/A
- Revenue Next Year
- DTIL N/A
- IRD $29.37
- P/E Ratio
- DTIL $4.07
- IRD N/A
- Revenue Growth
- DTIL 43.62
- IRD N/A
- 52 Week Low
- DTIL $3.61
- IRD $0.81
- 52 Week High
- DTIL $19.43
- IRD $2.65
- Technical
- Relative Strength Index (RSI)
- DTIL 63.88
- IRD N/A
- Support Level
- DTIL $4.60
- IRD N/A
- Resistance Level
- DTIL $5.23
- IRD N/A
- Average True Range (ATR)
- DTIL 0.36
- IRD 0.00
- MACD
- DTIL 0.13
- IRD 0.00
- Stochastic Oscillator
- DTIL 88.67
- IRD 0.00
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.